AbbVie drug approval sets up competition with Biohaven in migraine prevention September 29, 2021 Auto Bot AbbVie, BioPharma, Clinical Trials, FDA, Illinois, Legal, Migraine, North Chicago, Pharma, Qulipta 0 AbbVie drug Quilpta, developed specifically for migraine prevention, is now FDA approved, the latest product in a new class of migraine medicines. The AbbVie drug is the second oral migraine prevention drug that the FDA has approved this year.